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OBJECTIVEdTo evaluate the safety and efﬁcacy of closed-loop insulin delivery in well-
controlled pregnant women with type 1 diabetes treated with continuous subcutaneous insulin
infusion (CSII).
RESEARCH DESIGN AND METHODSdA total of 12 women with type 1 diabetes
(aged 32.9 years, diabetes duration 17.6 years, BMI 27.1 kg/m2, and HbA1c 6.4%) were ran-
domly allocated to closed-loop or conventional CSII. They performed normal daily activities
(standardized meals, snacks, and exercise) for 24 h on two occasions at 19 and 23 weeks’
gestation. Plasma glucose time in target (63–140 mg/dL) and time spent hypoglycemic were
calculated.
RESULTSdPlasma glucose time in target was comparable for closed-loop and conventional
CSII (median [interquartile range]: 81 [59–87] vs. 81% [54–90]; P = 0.75). Less time was spent
hypoglycemic (,45 mg/dL [0.0 vs. 0.3%]; P = 0.04), with a lower low blood glucose index
(2.4 [0.9–3.5] vs. 3.3 [1.9–5.1]; P = 0.03), during closed-loop insulin delivery.
CONCLUSIONSdClosed-loop insulin delivery was as effective as conventional CSII, with
less time spent in extreme hypoglycemia.
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There is strong evidence that avoid-ance of hyperglycemia is key to im-proved pregnancy outcomes in type
1 diabetes. Currently, the price to pay for
tight glucose control is increased risk of
severe hypoglycemia, causing signiﬁcant
maternal morbidity (seizures, road-trafﬁc
accidents, and death) (1). Despite the
increased use of insulin pumps and
fast-acting insulin analogs, continuous
glucose monitoring (CGM) highlights
the prevalence of hypoglycemia expo-
sure (3 h per day at ,70 mg/dL and
1 h per day at ,50 mg/dL) during preg-
nancy (2). Although the neonatal conse-
quences of maternal hypoglycemia are
unclear, it is accepted that the beneﬁts
of tight glycemic control must be bal-
anced against the potential risk of hypo-
glycemia (3).
Closed-loop systemsuse computerized
algorithms to link insulin delivery with
CGM glucose levels in real time, aiming to
more closely approximate normal glucose
concentrations. Overnight studies in chil-
dren and adults indicate the potential for
reduced nocturnal hypoglycemia (4,5).
We previously documented the effective-
ness of overnight closed-loop deliver in
early- and late-gestation type 1 diabetic
pregnancy, with 84–100% time in target
without nocturnal hypoglycemia during
sedentary conditions (6). The aim of this
study was to evaluate the safety and efﬁ-
cacy of 24-h closed-loop insulin delivery,
incorporating normal daily activities and
exercise.
RESEARCH DESIGN AND
METHODSdFrom April 2010 to April
2011, 12 pregnant women with type 1
diabetes from two U.K. antenatal clinics
(Addenbrooke’s Hospital, Cambridge,
U.K., and Kings College Hospital, London,
U.K.) were recruited into a randomized
crossover trial of closed-loop insulin de-
livery. The same study protocol com-
paring closed-loop and conventional
continuous subcutaneous insulin infu-
sion (CSII) was applied for two 24-h vis-
its, separated by a 1- to 6-week interval.
Study protocols were approved by the
research ethics committee, and all par-
ticipants provided written informed
consent.
Study devices and procedures
A FreeStyle Navigator sensor (Abbott Di-
abetes Care, Alameda, CA) was inserted
the day before each study. An intravenous
sampling catheter and study pump (Animas
2020; Johnson&Johnson,NewBrunswick,
NJ) were inserted on arrival (1200 h). After
lunch (50 g carbohydrate), an Actiheart
physical activity energy expenditure (PAEE)
monitor (CamNtech, Cambridge, U.K.)
was attached (7). From 1400 h, venous
samples were obtained every 15–30 min
until the study ended at 1230 h on day 2.
Plasma glucose concentrations were mea-
sured immediately (YSI 2300 STAT Plus
Analyzer; Farnborough,U.K.), with plasma
extracted for later insulin concentration
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measurements by immunochemilumi-
nometric assay (Invitron, Monmouth,
U.K.).
Daily activities
Activities included three 20-min walks
(1400, 1930, and 0900 h) and two 50-min
sessions of brisk treadmill walking (1500 h
on day 1 and 0930 h on day 2). Meal and
snack choices were consistent between vis-
its. Pre-exercise snackswere given according
to capillary glucose measurements (15 g
carbohydrate .108 mg/dL and 30 g car-
bohydrate #108 mg/dL). An additional
15-g carbohydrate snack was provided
at 2100 h.
Insulin delivery
During closed-loop, basal insulin infu-
sion rates were manually adjusted at 15-
min intervals according to CGM glucose
levels and the control algorithm advice.
During conventional CSII, the women set
temporary basal rates and used correction
boluses according to capillary glucose
measurements (7–10 per day). During
both visits, insulin boluses were calcu-
lated by women according to capillary
glucose levels, aiming for the National In-
stitute for Health and Clinical Excellence
(NICE)-recommended target glucose range
of 63–140 mg/dL (8).
Hypoglycemia
Hypoglycemia was deﬁned as plasma glu-
cose levels #54 mg/dL with symptoms or
#45 mg/dL without symptoms. Episodes
were treated with 15 g oral carbohydrate
(90mL Lucozade Energy Original; Glaxo-
SmithKline, Middlesex, England, U.K.).
Statistical analysis
The primary outcome was plasma glu-
cose time in target (63–140 mg/dL) from
1400 h on day 1 to 1230 h on day 2. Sec-
ondary outcomes were time spent above
and below target, mean glucose concentra-
tion, glucose SD, and low blood glucose
index (LBGI). The Wilcoxon signed rank
test was used to compare paired measure-
mentswithin an individual between closed-
loop and CSII visits. Values are given as
medians (interquartile ranges), unless oth-
erwise stated. Analyses were conducted us-
ing SPSS version 15 (SPSS, Chicago, IL).
RESULTSdParticipants (n = 12) had a
median age of 32.9 years (30.4–36.7), di-
abetes duration of 17.6 years (8.0–27.3),
CSII duration of 2.0 years (0.8–2.0),
weight of 77.0 kg (68.5–84.6), BMI of
27.1 kg/m2 (25.3–30.8), and HbA1c of
6.4% (6.1–6.6). A total of 11women started
CSII preconception, and 7 were prima-
parous. Studies were performed at 19
weeks’ (16–25) and 23weeks’ (20–28) ges-
tation, with a between-visit interval of 27
days (17–34). The primary and secondary
outcome data are shown in Table 1, with
details of the glycemic control achieved
shown in the Supplementary Data. There
was comparable median [interquartile
range] plasma glucose time in target be-
tween closed-loop and CSII visits (81
[59–88] vs. 81% [54–90]; P = 0.75).
Hypoglycemia
There were 13 hypoglycemic episodes
(8 symptomatic and 5 asymptomatic)
during closed-loop delivery versus 20 hy-
poglycemic episodes (17 symptomatic and
3 asymptomatic) during CSII, including
3 episodes below 36mg/dL.During closed-
loop delivery, the LBGI was lower (P =
0.03), with less time spent below 45
mg/dL (P = 0.04).
Overnight glucose control
The overnight plasma glucose time in tar-
get was strikingly high, with no differences
Table 1dPrimary and secondary outcomes during closed-loop and conventional CSII
Closed-loop delivery CSII P
Primary outcome
Plasma glucose time in target
Percentage of time in target (63–40 mg/dL) 81 (59–88) 81 (54–90) 0.75
Secondary outcomes
Plasma glucose outcomes
Mean plasma glucose (mg/dL) 108 (99–121) 104 (92–108) 0.35
SD of plasma glucose (mg/dL) 25.2 (23.4–37.8) 28.8 (25.2–41.4) 0.69
Hypoglycemia
Percentage of time hypoglycemic ,63 mg/dL 6.9 (1.3–12) 7.5 (3.6–18) 0.48
Percentage of time hypoglycemic #50 mg/dL 0.6 (0.0–2.1) 1.5 (0.0–2.7) 0.17
Percentage of time hypoglycemic #45 mg/dL 0.0 (0.0–0.2) 0.3 (0.0–1.5) 0.04
Symptomatic hypoglycemia 8 17
Episodes .45–54 mg/dL 8 12
Episodes .36–45 mg/dL 5 5
Episodes ,36 mg/dL 0 3
LBGI* 2.4 (0.9–3.5) 3.3 (1.9–5.1) 0.03
Hyperglycemia
Percentage of time hyperglycemic .140 mg/dL 14.0 (6.8–28) 6.7 (5.8–22) 0.75
Percentage of time hyperglycemic $180 mg/dL 0.2 (0.0–6.0) 0.0 (0.0–6.2) 0.78
High blood glucose index 0.8 (0.3–1.6) 0.4 (0.3–1.4) 0.81
PAEE (kJ/kg) 23.4 (19.7–27.0) 21.2 (19.0–22.1) 0.09
Insulin
Insulin infusion (units/h) 0.7 (0.5–0.9) 0.8 (0.5–1.1) 0.35
SD insulin infusion rate 0.9 (0.5–1.0) 0.2 (0.2–0.5) ,0.001
Plasma insulin concentration 120 (101–146) 107 (82–145) 0.88
Data are median (interquartile range), unless otherwise indicated. *LBGI assessed the duration and extent of hypoglycemia.
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between visits (95 [84–100] vs. 100% [64–
100]). However, during conventional
CSII, there was signiﬁcantly less overnight
time spent in target by CGM glucose meas-
urements (98 [94–100] vs. 83% [50–100];
P = 0.03). There were no discrepancies be-
tween plasma and CGM measurements
during any other time period.
CONCLUSIONSdIn this cohort of
pregnant women with tight glycemic
control, closed-loop insulin delivery was
as effective as conventional CSII but po-
tentially safer because closed-loop delivery
reduced the extent and duration of hypo-
glycemia.
Although there were fewer episodes
of hypoglycemia, decreased LBGI, and
less time spent below 45 mg/dL, closed-
loop delivery could not prevent exercise-
related hypoglycemia. Even algorithms
incorporating glucagon cannot prevent ex-
ercise-related hypoglycemia if there is a
rapid glucose reduction, increased insulin
on board, or sensor inaccuracy (9,10).
The ﬁnding that overnight time in
target measured by CGM, rather than
plasma glucose, favors closed-loop delivery
warrants additional consideration. Plasma
glucose measurements are impractical for
home studies, so establishing the optimal
means of assessing overnight closed-loop
delivery is important.
The strengths of this study include a
robust crossover design, standardized
meals, and physical activity to approximate
a real-life setting. Limitations are the small
sample size and that the system was not
fully automated. The achievement of 100%
overnight time in target provides support
for the further investigation of closed-loop
systems in pregnancy. Home testing over
multiple nights now is required to deter-
mine whether the near-optimal overnight
glucose control can be translated into longer-
term real-life beneﬁts.
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